开发PCSK9向的纳米粒子疫苗,有效降低高胆固醇血清症
Qiannan Fang1, Xinyu Lu2, Yuanqiang Zhu3
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.
Cell reports. Medicine
|June 19, 2024
概括
一种针对PCSK9 (proprotein convertase subtilisin/kexin type 9) 的新型纳米粒子疫苗有效降低胆固醇并减少动脉样硬化. 这种创新的疫苗显示出治疗高胆固醇血症和相关心血管疾病的前景.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 在调节低密度脂蛋白受体 (LDLR) 降解方面发挥着关键作用,导致LDL胆固醇升高.
- 升高的LDL胆固醇是动脉样硬化和心血管疾病的主要危险因素.
- PCSK9已成为管理高胆固醇血症的重要治疗点.
研究的目的:
- 开发和评估一种针对PCSK9.9的新型纳米粒子 (NP) 疫苗.
- 在临床前模型中评估疫苗在降低血清脂质和减轻动脉样硬化的有效性.
- 阐明疫苗治疗作用背后的免疫和细胞机制.
主要方法:
- 将PCSK9的催化域与自组装的24-米尔费里NP结合,以创建PCSK9 NP疫苗.
- 在高脂肪饮食引起的高胆固醇血症和AAV-hPCSK9引起的高胆固醇血症小鼠模型中对疫苗的评估.
- 在相关的小鼠模型中评估动脉样硬化斑块负担和巨细胞透.
- 研究T毛囊辅助细胞和LDLR在疫苗疗效中的作用.
主要成果:
- PCSK9 NP疫苗成功诱导了针对PCSK9的干扰抗体.
- 在这两种高胆固醇血清模型中都观察到血清脂质水平的显著降低.
- 该疫苗显著减少了动脉样硬化斑块区域和大动脉中的巨细胞透.
- 疫苗的有效性被证明取决于T毛囊辅助细胞和LDLR.
结论:
- 开发的PCSK9 NP疫苗是对高胆固醇血症的有希望的免疫治疗策略.
- 这种新型疫苗在临床前模型中有效降低了动脉样硬化进展.
- 这些发现支持PCSK9 NP疫苗作为心血管疾病新疗法的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


